KR102668252B1 - 아르기나제 저해제 및 이의 사용 방법 - Google Patents

아르기나제 저해제 및 이의 사용 방법 Download PDF

Info

Publication number
KR102668252B1
KR102668252B1 KR1020217007915A KR20217007915A KR102668252B1 KR 102668252 B1 KR102668252 B1 KR 102668252B1 KR 1020217007915 A KR1020217007915 A KR 1020217007915A KR 20217007915 A KR20217007915 A KR 20217007915A KR 102668252 B1 KR102668252 B1 KR 102668252B1
Authority
KR
South Korea
Prior art keywords
aza
oxa
hydroxy
boraspiro
dodecane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217007915A
Other languages
English (en)
Korean (ko)
Other versions
KR20210049120A (ko
Inventor
데동 우
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20210049120A publication Critical patent/KR20210049120A/ko
Application granted granted Critical
Publication of KR102668252B1 publication Critical patent/KR102668252B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/22Boron compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020217007915A 2018-08-22 2019-08-21 아르기나제 저해제 및 이의 사용 방법 Active KR102668252B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862721113P 2018-08-22 2018-08-22
US62/721,113 2018-08-22
PCT/EP2019/072341 WO2020038983A1 (en) 2018-08-22 2019-08-21 Arginase inhibitors and methods of use thereof

Publications (2)

Publication Number Publication Date
KR20210049120A KR20210049120A (ko) 2021-05-04
KR102668252B1 true KR102668252B1 (ko) 2024-05-21

Family

ID=67742403

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217007915A Active KR102668252B1 (ko) 2018-08-22 2019-08-21 아르기나제 저해제 및 이의 사용 방법

Country Status (25)

Country Link
US (1) US11952392B2 (https=)
EP (2) EP4371614A3 (https=)
JP (1) JP7441210B2 (https=)
KR (1) KR102668252B1 (https=)
CN (1) CN112584900B (https=)
AU (1) AU2019323663B2 (https=)
CA (1) CA3109100A1 (https=)
CL (1) CL2021000430A1 (https=)
DK (1) DK3840837T3 (https=)
EA (1) EA202190532A1 (https=)
ES (1) ES2980252T3 (https=)
FI (1) FI3840837T3 (https=)
HR (1) HRP20240694T1 (https=)
HU (1) HUE066903T2 (https=)
IL (1) IL280924B2 (https=)
LT (1) LT3840837T (https=)
MA (1) MA53427B1 (https=)
MX (1) MX2021002042A (https=)
PL (1) PL3840837T3 (https=)
PT (1) PT3840837T (https=)
RS (1) RS65608B1 (https=)
SG (1) SG11202101618PA (https=)
SI (1) SI3840837T1 (https=)
SM (1) SMT202400221T1 (https=)
WO (1) WO2020038983A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI877770B (zh) 2018-02-27 2025-03-21 美商英塞特公司 作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
WO2020010197A1 (en) 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
PH12021551902A1 (en) * 2019-02-08 2022-08-01 Astrazeneca Ab Arginase inhibitors and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011133653A1 (en) 2010-04-22 2011-10-27 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
WO2016210106A1 (en) 2015-06-23 2016-12-29 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
WO2018089490A1 (en) 2016-11-08 2018-05-17 Calithera Biosciences, Inc. Arginase inhibitor combination therapies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114989205A (zh) 2016-12-22 2022-09-02 卡里塞拉生物科学股份公司 用于抑制精氨酸酶活性的组合物和方法
CN117186134A (zh) 2018-02-17 2023-12-08 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
EP3765006A4 (en) 2018-03-13 2022-02-23 Merck Sharp & Dohme Corp. ARGINASE INHIBITORS AND METHODS OF USE
CN111770756B (zh) 2018-04-27 2023-03-31 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011133653A1 (en) 2010-04-22 2011-10-27 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
WO2016210106A1 (en) 2015-06-23 2016-12-29 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
WO2018089490A1 (en) 2016-11-08 2018-05-17 Calithera Biosciences, Inc. Arginase inhibitor combination therapies

Also Published As

Publication number Publication date
CL2021000430A1 (es) 2021-09-03
EP4371614A2 (en) 2024-05-22
JP2021535111A (ja) 2021-12-16
EP3840837B1 (en) 2024-03-20
HUE066903T2 (hu) 2024-09-28
MA53427B1 (fr) 2024-06-28
KR20210049120A (ko) 2021-05-04
AU2019323663B2 (en) 2022-07-14
MX2021002042A (es) 2021-04-28
SMT202400221T1 (it) 2024-07-09
IL280924B1 (en) 2024-06-01
PL3840837T3 (pl) 2024-08-19
IL280924B2 (en) 2024-10-01
IL280924A (en) 2021-04-29
US20210332068A1 (en) 2021-10-28
ES2980252T3 (es) 2024-09-30
PT3840837T (pt) 2024-06-14
FI3840837T3 (fi) 2024-06-03
SG11202101618PA (en) 2021-03-30
US11952392B2 (en) 2024-04-09
JP7441210B2 (ja) 2024-02-29
EP4371614A3 (en) 2025-09-24
CN112584900A (zh) 2021-03-30
AU2019323663A1 (en) 2021-04-08
EP3840837A1 (en) 2021-06-30
WO2020038983A1 (en) 2020-02-27
SI3840837T1 (sl) 2024-07-31
RS65608B1 (sr) 2024-07-31
LT3840837T (lt) 2024-06-10
CA3109100A1 (en) 2020-02-27
HRP20240694T1 (hr) 2024-08-16
MA53427A (fr) 2021-12-01
EA202190532A1 (ru) 2021-07-08
CN112584900B (zh) 2025-07-15
DK3840837T3 (da) 2024-06-10

Similar Documents

Publication Publication Date Title
KR102668252B1 (ko) 아르기나제 저해제 및 이의 사용 방법
CN113004269B (zh) Kras-G12C抑制剂杂环化合物
JP7699171B2 (ja) アルギナーゼインヒビタ及びその使用方法
EP0598129B1 (en) Novel tetrapeptide derivative
EP4667469A1 (en) Compound containing trifluoromethylsulfonyl
HK40110939A (en) Arginase inhibitors and methods of use thereof
HK40055578B (en) Arginase inhibitors and methods of use thereof
HK40055578A (en) Arginase inhibitors and methods of use thereof
HK40042067B (zh) 精氨酸酶抑制剂及其使用方法
EA042333B1 (ru) Ингибиторы аргиназы и способы их применения
HK40042067A (en) Arginase inhibitors and methods of use thereof
KR102885194B1 (ko) 아르기나제 저해제 및 이의 사용 방법
HK40112613A (en) Fused imide derivative

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210317

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220812

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240305

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240510

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240517

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240517

End annual number: 3

Start annual number: 1

PG1601 Publication of registration